Highlights Viva Biotech Holdings

Equities

1873

KYG9390W1015

Market Closed - Hong Kong S.E. Other stock markets 01:38:34 21/06/2024 pm IST			5-day change	1st Jan Change
0.53 ^HKD	0.00%		-13.11%	-49.52%

28/03	Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/01	Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
VIVA Biotech Redeems $280 Million Convertible Bonds Ahead of 2025 Maturity	03/01	MT
VIVA Biotech Sells 2.3% Stake in Viva Biotech (Shanghai)	27/12	MT
VIVA Biotech Disposes of Minority Stake in Subsidiary for $15 Million	18/12	MT
Viva Biotech Buys Back $143.4 Million Convertible Bonds	28/11	MT
Viva Biotech Buys Back $56.3 Million of Convertible Bonds Due 2025	21/11	MT
Viva Biotech Disposes 24% Stake in Subsidiary	20/11	MT
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) completed the acquisition of an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings.	20/11	CI
Viva Biotech Completes Post-Issue Regulatory Filing for Convertible Bonds	26/23/26	MT
Viva Biotech Buys Back $43 Million of 1% Convertible Bonds	13/23/13	MT
Viva Biotech Holdings commences an Equity Buyback Plan for 193,503,680 shares, representing 10% of its issued share capital, under the authorization approved on June 30, 2023.	28/23/28	CI
Viva Biotech Logs 64% Jump in H1 Profit	30/23/30	MT
Viva Biotech Holdings Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Viva Biotech to Swing to H1 Profit	18/23/18	MT
Viva Biotech Holdings to Sell 24% of Subsidiary for 1.06 Billion Yuan	09/23/09	MT
Viva Biotech Issues HK$470 Million in Convertible Bonds; Shares Fall 12%	12/23/12	MT
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) entered into an agreement to acquire an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings for CNY 514.6 million.	11/23/11	CI
Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Viva Biotech to Swing to FY22 Loss	16/23/16	MT
Viva Biotech Holdings Provides Group Earnings Guidance for the Year Ended December 31, 2022	16/23/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Viva Biotech Holdings

Equities

1873

KYG9390W1015

Highlights

Filters